Stefan Lohmer is a co-founder and Chief Executive Officer of Axxam since 2001. Prior to founding Axxam, he was the Director of Bayer’s Research Centre in Milan (Italy) and the Head of Genomics worldwide for Bayer AG. In this function Stefan was responsible for generating and managing Bayer’s external genomic alliance with Millennium Pharmaceuticals (Cambridge, USA). He joined Bayer at the corporate research center located at Wuppertal (Germany) in 1992. Stefan holds a degree in Molecular Biology and Biochemistry from the Albertus Magnus University in Cologne (Germany) and completed his PhD at the Max-Planck-Institute for Plant Breeding in Cologne. He is an inventor on more than 20 patents and has authored more than 20 peer-reviewed publications.
Stefan serves in the Board of Directors of Rewind Therapeutics, Libra Therapeutics, and Golgi Neurosciences as well being an Observer in the Board of Acousia Therapeutics.
Stefan is passionate about transformative science and creating companies.
“Never follow the path, always set the trail!”